Diane McKeeff, NP
Adult Health · Wakefield, RINPI 1003816117
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 67 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AbbVie at 32.9% of the total. Reporting peaked in 2023 at $606 and has fallen 80.6% since, to $118 in 2025.
Across 67 payments — averaging $21.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$464
- AstraZeneca$223
- Lilly USA, LLC$135
- Pfizer$115
- Biohaven Pharmaceuticals, Inc.$72
- Novo Nordisk$59
- plus $343 from 11 others
What the payments were for
- Food & beverage$1,411100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 22 | $464 |
| AstraZeneca | 8 | $223 |
| Lilly USA, LLC | 6 | $135 |
| Pfizer | 6 | $115 |
| Biohaven Pharmaceuticals, Inc. | 3 | $72 |
| Novo Nordisk | 3 | $59 |
| Lundbeck LLC | 3 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $44 |
| Exact Sciences | 2 | $44 |
| Bayer | 2 | $42 |
| Boehringer Ingelheim | 2 | $39 |
| Vanda Pharmaceuticals Inc. | 2 | $30 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $28 |
| Endo Pharmaceuticals Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $19 |
| Rhythm Pharmaceuticals, Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$102
How this compares
$1,411 in reported general payments places this provider in the 80th percentile of 65 adult health providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 88 | $88,667 |
| EliquisApixaban | 69 | $66,160 |
| JardianceEmpagliflozin | 57 | $65,303 |
| XareltoRivaroxaban | 24 | $22,241 |
| TrulicityDulaglutide | 17 | $15,452 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $11,584 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $10,516 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $8,856 |
| Atorvastatin Calcium | 527 | $5,598 |
| Omeprazole | 226 | $3,474 |
| Levothyroxine Sodium | 298 | $3,448 |
| Losartan Potassium | 298 | $3,315 |
| Humulin 70/30 KwikpenInsulin Nph Hum/Reg Insulin Hm | 11 | $2,543 |
| Rosuvastatin Calcium | 135 | $2,400 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 80 | $2,196 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $59 | $88,66788 claims |
| PfizerEliquis | $115 | $66,16069 claims |
| Boehringer IngelheimJardiance | $39 | $65,30357 claims |
| Johnson & JohnsonXarelto | $19 | $22,24124 claims |
| Lilly USA, LLCTrulicity | $135 | $15,45217 claims |
| AstraZenecaBreztri Aerosphere | $223 | $11,58419 claims |
| AbbVieSynthroid | $464 | $2,15040 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 65 adult health providers in Rhode Island.
Other adult health in Wakefield
- Patricia KarwanWakefield$1K
- Jacqueline AlbrikesJohnston$14K
- Elizabeth McGrathBarrington$7K
- Kathleen FranchinaWarwick$5K
- Deirdre CoutureCranston$5K
- Janine ZuromskiEast Greenwich$5K
- Christine UyProvidence$4K
- Kathleen RasslerEast Greenwich$3K
- Lindsay LeddyWarwick$3K
- Phina MayuProvidence$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.